Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
May 20 2019 - 4:05PM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic
pharmaceutical company, today announced that it received a new
Abbreviated New Drug Application (ANDA) approval from the U.S. Food
and Drug Administration (FDA) for Azelastine Hydrochloride Nasal
Spray, 0.1%.
According to IQVIA, U.S. sales of Azelastine Hydrochloride Nasal
Spray, 0.1% were approximately $46 million for the twelve months
ended March 2019. Azelastine Hydrochloride Nasal Spray, 0.1% is
indicated for the treatment of the symptoms of seasonal allergic
rhinitis in adults and pediatric patients 5 years and older, and
for the treatment of the symptoms of vasomotor rhinitis in adults
and adolescent patients 12 years and
older.About AkornAkorn, Inc. is a
specialty generic pharmaceutical company engaged in the
development, manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities
located in Decatur, Illinois; Somerset, New
Jersey; Amityville, New York;
Hettlingen, Switzerland and Paonta
Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website
at www.akorn.com.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Apr 2023 to Apr 2024